drugset / Trial / NCT01718301
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha 2a) and Ribavirin in HIV/HCV genotype 1 infected patients that failed to previous HCV therapy.
Timeline
- Start
- 2013-03-10
- Primary completion
- 2015-03-20
- Completion
- 2015-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Boceprevir | Small molecule | 800 mg | Oral |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Peginterferon alfa-2b | Protein / enzyme biologic | — | — |
| Background | Ribavirin | Small molecule | — | — |